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Table. Incremental and attributable hospital costs associated with
peri-procedural complications of TAVR
Complication
Incremental
Cost
(per event)
Attributable Cost (per patient)
Overall
(n ¼ 506)
IF group
(n ¼ 397)
Non-IF
group
(n ¼ 109)
Death $10,176 $519 $509 $560
Major Stroke $20,769 $623 $312 $1,724
AKI Stage 3 $29,587 $473 $444 $533
Bleeding
Life-threatening $15,845 $2,123 $1,870 $3,058
Major $7,130 $1,932 $1,740 $2,617
Arrhythmia $7,740 $1,618 $1,440 $2,276
Perm. Pacemaker Implant $13,861 $2,523 $2,717 $1,774
Repeat TAVR $116,732 $934 $1,167 –
Total Cost of Complications $10,745 $10,197 $12,541
R2 of model ¼ 0.36
IF¼Iliofemoral access; Non-IF¼Non-iliofemoral access; AKI ¼ acute kidney injury
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Background: Only few data are available on the impact of mixed aortic stenosis
(MAS) on clinical outcomes and post-procedural aortic regurgitation (PPAR) after
transcatheter aortic valve implantation (TAVI). The aim of this study was to assess the
impact of MAS on PPAR and clinical outcomes after TAVI.
Methods: Data from a multicenter registry were retrospectively analysed. Outcomes
were compared between patients with pure aortic stenosis (PAS; associated AR
< 1+/3+) and MAS (associated AR  1+/3+). Study objectives were PPAR incidence
and Valve Academic Research Consortium 2 (VARC-2) outcomes at long-term
follow-up.
Results: In total, 1091 patients were included: 432 (39.5%) with MAS and 659
(60.4%) with PAS. At 30 days, there were no differences in all-cause (6.4% vs. 6.3%;
p ¼ 0.930) and cardiovascular mortality (5.5% vs. 4.2%; p ¼ 0.315), however a
greater incidence of major bleeding (23% vs. 16.5%; p ¼ 0.011), spontaneous
myocardial infarction (2% vs. 0.3%; p ¼ 0.019) and PPAR  1+/3+ (43% vs. 27%;
p < 0.001) was observed in patients with MAS. Of note, MAS was an independent
predictor of PPAR  1+/3+ at multivariable analysis. At a median follow-up period of
421 days (IQR 252 – 710), patients with MAS had a higher all-cause (30% vs. 24%;
p ¼ 0.047) and cardiovascular mortality (17% vs. 12%; p ¼ 0.023). Conversely, in
patients that developed PPAR  2+/3+ the presence of baseline MAS was associated
with a trend of lower long-term all-cause and cardiovascular mortality (46% vs. 73%,
p ¼ 0.188 and 17% vs. 50%, p ¼ 0.095).
Conclusions: MAS was associated with a higher PPAR incidence and increased all-
cause and cardiovascular mortality when compared to patients with PAS. However, in
patients who developed PPAR  2+/3+, baseline MAS trended to be associated with
improved long-term survival.
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Background: In patients (pts) with severe aortic stenosis, transcatheter aortic valve
replacement (TAVR) improves survival compared with medical therapy but is asso-
ciated with higher costs. Prior studies have shown that peri-procedural complications
have a sizeable effect on cost in pts treated with a balloon-expandable prosthesis, but
no studies to date have examined the impact of complications on costs in pts treated
with a self-expanding prosthesis.B200 JACC Vol 64/11/Suppl B j SepMethods: Using hospital cost data from 506 pts enrolled in the CoreValve US Pivotal
Extreme Risk study, we developed multivariable models to estimate the incremental
cost associated with speciﬁc complications of TAVR. Complications were deﬁned
according to the VARC-1 criteria and adjudicated by an independent events com-
mittee. Attributable costs were calculated by multiplying the incremental cost of each
event by its frequency.
Results: Mean cost for the initial hospitalization (including physician fees and cost of
the valve) was $73,701 + 26,981. Overall, complications accounted for $10,197 per pt in
the ilio-femoral access (IF) cohort and $12,541 per pt in the non-IF access cohort (25%
and 27% of non-implant related costs, respectively). For IF pts, permanent pacemaker
implantation and bleeding complications accounted for the largest attributable cost,
whereas bleeding complications and arrhythmias contributed most in non-IF pts.
Conclusions: In this initial US experience with the Medtronic CoreValve device, peri-
procedural complications accounted for up to 27% of non-implant related hospital
costs. Both the absolute and relative cost increases were greater among pts treated via
a non-IF approach. In the future, avoidance of complications should improve the cost-
effectiveness of TAVR in inoperable pts treated with a self-expanding prosthesis –
particularly for pts unsuitable for IF access.TCT-686
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Background: Aortic stenosis (AS) induces adaptive left ventricular (LV) remodeling,
with some geometric patterns associated with increased morbidity and mortality after
surgical aortic valve replacement (AVR). Whether the geometric pattern of LV
remodeling at baseline impacts outcomes after transcatheter AVR (TAVR) remains
unknown.
Methods: The PARTNER randomized trial and continued access registry included
high-risk (n¼2,184) and inoperable (n¼508) patients with symptomatic severe AS.
Using relative wall thickness cut points for concentric geometry (>0.42) and sex-
speciﬁc LV mass index thresholds for severe LV hypertrophy (>149 g/m2 for men
and >122 g/m2 for women) on baseline echocardiograms, patients were stratiﬁed into
four LV geometric patterns: normal geometry, concentric remodeling (cLVR),
concentric hypertrophy (cLVH), and eccentric hypertrophy (eLVH). Clinical out-
comes associated with each geometric pattern were assessed.
Results: Of 2,692 patients (mean age, 85 years; 52% male) with mean LV ejection
fraction 5213%, normal geometry, cLVR, cLVH, and eLVH were present in 13, 37,
40, and 10%, respectively. Rates of all-cause and cardiac death were comparable
across groups at 30 days. Patients with normal LV geometry demonstrated the worst
survival at 6 months (20.7% vs 14.6% with cLVR; P¼0.008) and 1 year (26.2% vstember 13–17, 2014 j TCT Abstracts/Valvular disease - Aortic: TAVR
www.jacctctabstracts2014com SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM21.3% with cLVR; P¼0.05; Table). Rates of repeat hospitalization did not differ
between groups. Risk of myocardial infarction was greatest (3.5% vs 0.9% with
cLVH; P¼0.001) and stroke lowest (1.5 vs 6.2% with cLVH; P¼0.003) in the eLVH
goup at 1-year. Functional class and 6-minute walk distance were worst at all time
points in patients with baseline cLVH.Table. Clinical outcomes after TAVR stratiﬁed by baseline LV geometry.
Normal cLVR cLVH eLVH
P value
ANOVA
6-Month Outcomes
All-cause Death 20.70% 14.6%* 18.00% 18.60% 0.04
Cardiac Death 10.80% 5.9%* 8.80% 8.60% 0.02
Repeat
hospitalizations
14.60% 15.40% 16.00% 20.50% 0.22
Stroke 3.10% 4.00% 5.60% 1.5%* 0.02
Myocardial infarction 0.60% 1.10% 0.70% 3.5%** 0.002
1-Year Outcomes
All-cause Death 26.20% 21.30% 25.10% 26.80% 0.08
Cardiac Death 12.90% 9.20% 11.10% 10.80% 0.19
Repeat
hospitalizations
20.60% 19.10% 21.30% 25.00% 0.2
Stroke 3.90% 4.40% 6.20% 1.5%** 0.01
Myocardial infarction 1.00% 1.70% 0.90% 3.5%** 0.01
*Pairwise comparison P<0.0167 (Bonferroni-adjusted).
** Pairwise comparison P<0.005.Conclusions: In patients with symptomatic severe AS, geometric patterns of LV
remodeling at baseline are associated with differential risk of death, stroke, and
myocardial infarction after TAVR.
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Background: Transcatheter Aortic Valve Replacement (TAVR) has being increas-
ingly offered in low and intermediate surgical risk patients with severe aortic stenosis
(AS). The OBSERVANT study aims to describe 12-month clinical outcomes of a
large series of propensity-matched patients at low or intermediate risk undergoing
transfemoral TAVR and surgical aortic valve replacement (SAVR).
Methods: OBSERVANT is an observational prospective multicenter cohort study,
enrollingASpatients undergoing SAVRor TAVR.Data onmortality, hospitalizations at
follow-up andmajor complicationswere derived fromadministrative reports. Propensity
score method was applied to select two groups with similar baseline characteristics.
Results: The unadjusted enrolled population (N¼7,618) comprises 5,707 SAVR
patients and 1,911 TAVR patients. Matched population comprised a total of 1,300
patients (650 patients for each group). A population at intermediate risk was selected
(mean logistic EuroSCORE 10.29.2% vs. 9.57.1%, SAVR vs. transfemoral
TAVR; p¼0.104). Thirty-day mortality was 3.8% and 3.2% for SAVR and TAVR
(p¼0.546). The incidence of stroke and acute myocardial infarction was similar in the
two groups, whereas a higher requirement for blood transfusion was reported across
the surgical cohort (. 3.63.6 vs. 2.32.2 red blood cells units; p¼0.002). A higher
incidence of major access site complications (0.5% vs. 7.9%; p< 0.001) and per-
manent pacemaker implantation (3.6% vs. 15.5%; p< 0.001) were reported in the
TAVR group. 12-month mortality was 13.1% and 12.6% for SAVR and TAVR
(p¼0.313). Data regarding re-hospitalizations and other major complications at
12 months will be available for the presentation of the abstract
Conclusions: The results of this study show that transfemoral TAVR and SAVR have
comparable mortality outcomes at 12-month in patients with severe AS and at inter-
mediate surgical risk. At 30-day SAVR was associated with a higher risk for blood
transfusion, whereas TAVR showed a signiﬁcantly increased rate of vascular damage,
and permanent pacemaker requirement.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/VaTCT-688
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Background: Recent reports have documented the early utility of transcatheter valve
implantation within failed surgical bioprosthesis for patients at high risk for surgical
re-intervention. We sought to report outcomes of valve-in-valve (VIV) procedures at
one year, and to understand whether residual gradients impact clinical outcomes and
left ventricular mass regression (LVMR).
Methods: Patients with severe symptomatic stenosis, regurgitation, or mixed disease
of surgical bioprosthetic aortic valves who were at very high risk for repeat aortic
valve replacement surgery (mortality/morbidity >50%) were prospectively enrolled in
the multicenter PARTNER II VIV registry using the Sapien XT device.
Results: A total of 96 patients underwent VIV procedures. At baseline, the mean age
was 80.1 9.3 years and 45.8% of patients were female. The Society of Thoracic
Surgeons predicted risk of operative mortality was 9.9  5.1%. Labelled surgical
valve sizes (mm) were 21 in 31.5%, 23 in 41.3%, and >23 in 27.2%. The 23-mm XT
valve was implanted in 76.6% and the 26-mm valve in 23.4%.The predominant he-
modynamic manifestation of surgical aortic valve failure was classiﬁed as prosthetic
stenosis in 61%, regurgitation in 17% or combined steno-regurgitation in 22%. Thirty-
day all-cause mortality was 7.7%. One year all-cause mortality, rehospitalization,
stroke, adverse events and hemodynamic performance of the Sapien XT device uti-
lized for VIV therapy including residual gradients and LVMR are currently being
adjudicated and will be available at time of presentation.
Conclusions: Transcatheter aortic valve implantation within existing tissue valves is a
viable therapeutic modality for the management of high-risk patients with senescent
bioprosthetic devices. While short-term safety has been demonstrated, mid-term clinical
outcome and hemodynamic performance data are needed to fully understand the po-
tential of VIV procedures to alter the therapeutic landscape. In particular, the effect of
residual gradients and their impact on clinical outcomes and LVMR remain unknown.
TCT-689
Three- and Five-Year Outcomes After Transcatheter Aortic Valve Implantation
in High-Risk Patients With Severe Aortic Stenosis: The U.K. TAVI (United
Kingdom Transcatheter Aortic Valve Implantation) Registry
Alison Duncan1, Peter Ludman2, David Cunningham3, Damian Marlee3,
Simon Davies4, Neil Moat5
1Royal Brompton Hospital, London, London, 2University Hospital Birmingham,
Birmingham, Birmingham, 3University College London, London, United Kingdom,
4The Royal Brompton Hospital, London, United Kingdom, 5royal brompton hospital,
London, United Kingdom
Background: The United Kingdom Transcatheter Aortic Valve Implantation Registry
(U.K. TAVI Registry) reported 30-day and 1-year survival of 92.9% and 78.6%
respectively in patients undergoing TAVI. Few data are available on outcome beyond
3 years in any notable number of patients. The aim of this study was to report clinical
outcome 3- and 5-years after TAVI, regardless of technology or access route, using
data from UK TAVI registry
Methods: The U.K. TAVI Registry captured all TAVI procedures performed within
the UK from 01/01/2007 to 31/12/2009. Data were collected prospectively on 870
patients. Mortality status was reported as of July 2013, and mortality tracking was
achieved in 95.2% patients. Minimum follow-up was 3.54 years, maximum follow-up
was 6.36 years.
Results: Survival at 3-years and 5-years was 61.6% and 48.4% respectively. At 3-
years, survival was independently adversely affected by atrial ﬁbrillation (p¼0.018),
chronic obstructive pulmonary disease (COPD) (p¼0.034), renal dysfunction (Cr
>200mmol/L) (p¼0.008) and baseline Euroscore (18.45) (p0.012). At 5-years,
survival was independently adversely affected by age (p¼0.001), diabetes (p¼0.01),
atrial ﬁbrillation (0.009), chronic obstructive pulmonary disease (COPD) (p¼0.022),
renal dysfunction (Cr >200mmol/L) (p¼0.002), and baseline Euroscore (18.45)
(p0.026). Valve type (Edwards vs. Medtronic), access route (transfemoral vs. non-
transfemoral), or procedural complications (moderate/severe paravalvular aortic
regurgitation, major vascular complications, and need for permanent pacing) did not
predict mortality at either 3- or 5-years.
Conclusions: Almost half patients undergoing TAVI were alive after 5 years. Long-
term survival after TAVI is determined by intrinsic patient factors (age, diabetes, AF,
respiratory disease, renal impairment). Neither procedural nor device-related factors
were independent predictors of long-term mortality.lvular disease - Aortic: TAVR B201
